Fig. 2
Fig. 2 Zfyve9a is required for liver development. (A) A cartoon of the zfyve9a gene structure shown the positions of MO-AUG, MO-SP and primers used in RT-PCR reaction in (C). (B) MO-AUG (4 ng) effectively inhibited the translation of Zfyve9a-GFP mRNA (100 pg) as determined at about 70% epiboly stage. (C) RT-PCR analysis for the effect of MO-SP. PCR products from wild type and zfyve9a morphants were cloned and sequenced. The lower band in MO-SP treated sample corresponds to a deletion of the C-end of exon 2. (D) Representative live images of wild type embryo and zfyve9a morphants at day 3. (E-F) Expression of fabp10a in WT, MO-AUG or MO-SP injected embryos at day 3 (E) and day 4 (F). (G) Expression of another liver marker, cp, in WT embryos and zfyve9a morphants at day 4. (H-J) Knockdown of zfyve9a did not affect the development of pancreas or gut at day 4. insulin labels the pancreatic beta-cells, trypsin indicates the exocrine pancreas and fabp2 marks the intestine.